News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Seattle Genetics, Inc. (SGEN) And Collaborators Will Present Data From Multiple Antibody-Drug Conjugate (ADC) Programs At American Society of Clinical Oncology Annual Meeting


5/15/2014 8:10:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from multiple proprietary and collaborator antibody-drug conjugate (ADC) programs will be highlighted at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL.

With over 16 years of experience and knowledge in ADC innovation, Seattle Genetics is the leader in developing ADCs, a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES